ESR1 and breast carcinoma: It was previously shown that complete response rates to trastuzumab-based treatment are lower in patients with the highest ER expression levels in HER2-positive breast cancers, like ER and HER-positive BT-474 cells, compared to ER-negative and HER2-positive SK-BR-3 cells [37].